No annual revenue total was found in Structure Therapeutics Inc.'s SEC filings.
Structure Therapeutics Inc. (GPCR) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$225.8 million. As of Jun 30, 2026 it held $1.3 billion in cash and investments and $6.2 million in total debt.
Revenue
—
Net income (TTM)
$-214.84M
-20.1% vs year-ago TTM
Operating cash flow (TTM)
$-220.29M
-35.2% vs year-ago TTM
Free cash flow (TTM)
$-224.50M
-36.7% vs year-ago TTM
EPS (TTM)
$-1.07
-3.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
212.53M
+23.5% vs prior year
Net cash
$1.34B
as of Jun 30, 2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GPCR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- South San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1888886
- Former names
- ShouTi Inc. (until May 13, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
|---|---|---|---|
| Operating income | -$176.6M | -$158.2M | -$102.8M |
| Net income | -$141.2M | -$122.5M | -$89.6M |
| Diluted EPS | -$0.80 | -$0.78 | -$0.81 |
| Operating cash flow | -$222.2M | -$116.6M | -$79.5M |
| Free cash flow | -$225.8M | -$117.9M | -$81.7M |
| Total assets | $1.6B | $903.3M | $482.0M |
| Total liabilities | $67.5M | $38.5M | $29.1M |
| Stockholders' equity | $1.5B | $864.8M | $453.0M |
| Cash and investments | $1.4B | $883.5M | $467.3M |
| Total debt | $6.5M | $3.9M | $5.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 8, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 17, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, Other events
|
May 7, 2026 | May 7, 2026 |
All 271 Structure Therapeutics Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.